Zevra Q3 net loss narrows to $0.5M; revenue jumps to $26.1M on MIPLYFFA sales

ZEVRA THERAPEUTICS, INC.

2025-Q3 EPS reported $1.16 revenue$72,345,000

Q3 net revenue $26.1M (vs $3.7M YoY), with MIPLYFFA contributing $22.4M.
Net loss $(0.5)M or $(0.01) per share vs $(33.2)M or $(0.69) per share in Q3 2024.
MIPLYFFA prescription enrollment forms total 137 since launch; market access 66% of covered lives.
Cash and securities $230.4M as of Sep 30, 2025; company believes sufficient to fund operations.
Arimoclomol EMA application validated under review; celiprolol Phase 3 trial enrolled 44 patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.